Details for New Drug Application (NDA): 021862
✉ Email this page to a colleague
The generic ingredient in NEVANAC is nepafenac. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the nepafenac profile page.
Summary for 021862
Tradename: | NEVANAC |
Applicant: | Harrow Eye |
Ingredient: | nepafenac |
Patents: | 3 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 021862
Generic Entry Date for 021862*:
Constraining patent/regulatory exclusivity:
Dosage:
SUSPENSION/DROPS;OPHTHALMIC |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 021862
Mechanism of Action | Cyclooxygenase Inhibitors |
Suppliers and Packaging for NDA: 021862
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
NEVANAC | nepafenac | SUSPENSION/DROPS;OPHTHALMIC | 021862 | NDA | Novartis Pharmaceuticals Corporation | 0078-0778 | 0078-0778-03 | 3 mL in 1 BOTTLE (0078-0778-03) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | SUSPENSION/DROPS;OPHTHALMIC | Strength | 0.1% | ||||
Approval Date: | Aug 19, 2005 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Jan 31, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD OF TREATING OCULAR INFLAMMATION | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 2, 2025 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Dec 2, 2025 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 021862
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Harrow Eye | NEVANAC | nepafenac | SUSPENSION/DROPS;OPHTHALMIC | 021862-001 | Aug 19, 2005 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription